medigraphic.com
ISSN 1995-9427 (Print)

2023, Number 1

<< Back Next >>

Invest Medicoquir 2023; 15 (1)

Evaluación neuropsicológica en pacientes con esclerosis múltiple recaída remisión en tratamiento con Rebif

Cabrera AI, Díaz de la Fe A, Baez MM, Zamora PF, Martínez MMI, Robinson AMÁ, Díaz RB

Language: Spanish
References: 32
Page:
PDF size: 197.72 Kb.


ABSTRACT

Introduction. Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. It is considered as the most prevalent and disabling non-traumatic disease affecting the population of young and middle-aged adults. The presence of cognitive affections in these patients is known.
Objectives. To describe the superior psychic functions in patients with Multiple Sclerosis treated and not treated with Rebif and to identify the most affected functions.
Methods. We studied 26 patients treated at the International Center for Neurological Restoration, divided into two groups: 13 patients with Multiple Sclerosis (treated with Rebif) and 13 untreated patients. The clinical variables, such as subtype of MS, duration of disease, medication and neuropsychological profile were analyzed.
Results. the study showed that most of the patients treated and not treated with Rebif presented cognitive alterations. The most affected functions were attention, long-term memory and executive functions. Patients treated with Rebif reported fewer symptoms of depression than those not treated. No relationship was found between clinical variables and cognitive impairment.
Conclusions. The Superior Psychic Functions are affected in patients with Multiple Sclerosis treated and not treated with Rebif. Depression was lower in patients treated with Rebif.


REFERENCES

  1. Mahajan KR, Ontaneda D. The Role of Advanced Magnetic Resonance Imaging Techniquesin Multiple Sclerosis Clinical Trials. Neurotherapeutics. 2017;14(4):905-23.

  2. Schwenkenbecher P, Wurster U, Konen FF, Gingele S, Sühs KW, Wattjes MP, et al. Impact ofthe McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. Frontiersin Neurology. 2019;10.

  3. Makhani N, Lebrun C, Siva A, Narula S, Wassmer E, Brassat D, et al. Oligoclonal bandsincrease the specificity of MRI criteria to predict multiple sclerosis in children with radiologicallyisolated syndrome. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2019;5(1).

  4. Villa A CJ, Garcea O. Esclerosis Múltiple. Conceptos básicos y clínicos. Editorial Dunken.2008.

  5. Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez M, Meca-Lallana V,Ramió-Torrentà L. Cognitive Dysfunctions and Assessments in Multiple Sclerosis. Frontiers inNeurology. 2019;10.

  6. Papathanasiou A, Messinis L, Georgiou VL, Papathanasopoulos P. Cognitive Impairment inRelapsing Remitting and Secondary Progressive Multiple Sclerosis Patients: Efficacy of aComputerized Cognitive Screening Battery. ISRN Neurology. 2014;2014.

  7. Ruggieri RM, Palermo, R., Vitello, G., Gennuso, M., Settipani, N. y Piccoli. Cognitiveimpairment in patients suffering from relapsing-remitting multiple sclerosis with EDSS≤3.5. , , .Acta Neurologica Scandinavica. 2003;108:323-6.

  8. Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. Cognition inmultiple sclerosis: State of the field and priorities for the future. Neurology. 2018;90(6):278-88.

  9. Bakirtzis C, Ioannidis P, Messinis L, Nasios G, Konstantinopoulou E, Papathanasopoulos P,et al. The Rationale for Monitoring Cognitive Function in Multiple Sclerosis: Practical Issues forClinicians. The Open Neurology Journal. 2018;12:31-40.

  10. Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Squitieri F, Curcio G, et al. CognitiveImpairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability.Behavioural Neurology. 2017;2017.

  11. Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. Recommendations forcognitive screening and management in multiple sclerosis care. Multiple Sclerosis (Houndmills,Basingstoke, England). 2018;24(13):1665-80.

  12. Macías Islas M, Ciampi E. Assessment and Impact of Cognitive Impairment in MultipleSclerosis: An Overview. Biomedicines. 2019;7(1).

  13. Silveira C, Guedes R, Maia D, Curral R, Coelho R. Neuropsychiatric Symptoms of MultipleSclerosis: State of the Art. Psychiatry Investigation. 2019;16(12):877-88.

  14. Solaro C, Trabucco E, Signori A, Martinelli V, Radaelli M, Centonze D, et al. DepressiveSymptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An ItalianMulti-Center Study Using the Beck Depression Inventory. PLoS ONE. 2016;11(9).

  15. Fischer A, Fischer M, Nicholls RA, Lau S, Poettgen J, Patas K, et al. Diagnostic accuracy formajor depression in multiple sclerosis using self-report questionnaires. Brain and Behavior.2015;5(9).

  16. Wojcik CM, Beier M, Costello K, DeLuca J, Feinstein A, Goverover Y, et al. Computerizedneuropsychological assessment devices in multiple sclerosis: A systematic review. MultipleSclerosis (Houndmills, Basingstoke, England). 2019;25(14):1848-69.

  17. Klonoff H, Clark C, Oger J, Paty D, D L. Neuropsychological performance in patients withmild multiple sclerosis. J Nerv Ment Dis. 1999;179(3):127-31.

  18. Genova HM, DeLuca J, Chiaravalloti N, Wylie G. The Relationship between ExecutiveFunctioning, Processing Speed and White Matter Integrity in Multiple Sclerosis. Journal of clinicaland experimental neuropsychology. 2013;35(6):631-41.

  19. Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the SymbolDigit Modalities Test as a cognition performance outcome measure for multiple sclerosis. MultipleSclerosis (Houndmills, Basingstoke, England). 2017;23(5):721-33.

  20. MB AA-A, J O. Multiple sclerosis for the practicing neurologist New York: Demos MedicalPublishing. 2006;5.

  21. Beatty WW GD, et al. Cognitive disturbances in patients with relapsing remitting multiplesclerosis. 1989;46:1113-9.

  22. Jancic J, Nikolic B, Ivancevic N, Djuric V, Zaletel I, Stevanovic D, et al. Multiple Sclerosis inPediatrics: Current Concepts and Treatment Options. Neurology and Therapy. 2016;5(2):131-43.

  23. McGinley M, Rossman IT. Bringing the HEET: The Argument for High-Efficacy EarlyTreatment for Pediatric-Onset Multiple Sclerosis. Neurotherapeutics. 2017;14(4):985-98.

  24. Bobholz J, SM R. Cognitive dysfunction in multiple sclerosis: a review of recentdevelopments. Current Opinion in Neurology. 2003;16:183-88.

  25. Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti N, Dalgas U, et al. Studyprotocol: improving cognition in people with progressive multiple sclerosis: a multi-arm,randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise(COGEx). BMC Neurology. 2020;20.

  26. Lemos L, Guerra Júnior AA, Santos M, Magliano C, Diniz I, Souza K, et al. The Assessmentfor Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis inBrazil. Pharmacoeconomics. 2018;36(2):161-73.

  27. Arroyo E, Grau C, Ramo C, Parra J, O S-S. Estudio Global de adherencia a los tratamientosinmunomoduladores en pacientes con esclerosis múltiple remitente recidivante: resultado a 2años. Neurología. 2010;25(7):435-42.

  28. IM. M. Editorial Sheldon and Moo. 1968.

  29. Bruno A, Dolcetti E, Rizzo FR, Fresegna D, Musella A, Gentile A, et al. Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis. Frontiersin Cellular Neuroscience. 2020;14.

  30. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, SG H. Cognitive behavioraltherapy for anxiety and randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502-14.

  31. Costa DT, Sundberg M, Passos L, Muniz AL, Santos S. Interferon Beta-1a Improves UrinarySymptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP.Case Reports in Neurological Medicine. 2012;2012.

  32. Miller E, Morel A, Redlicka J, Miller I, J S. Pharmacological and Non-pharmacologicalTherapies of Cognitive Impairment in Multiple Sclerosis. Curr Neuropharmacol. 2018;16(4):475-83.




2020     |     www.medigraphic.com